In our mission to enable industrial scale genome editing for therapeutics and therefore making gene therapies universally affordable, Mekonos is developing a new approach for cell engineering using a proprietary silicon chip technology (KAREL) that delivers molecules into potentially, millions of individual cells. This will see a dramatic breakthrough in the genetic engineering treatment of diseases such as cancers.